INFORME INHATA - INFORME INHATA
Camino de migas
Publicador de contenidos
Objetivo: This health technology assessment evaluates the diagnostic accuracy, clinical utility, safety, and cost-effectiveness of cell-free circulating tumour DNA [ctDNA] blood testing (referred to in this report as “liquid biopsy”) to detect the resistance mutation epidermal growth factor receptor (EGFR) T790M in people with advanced non–small cell lung cancer (NSCLC). It also evaluates the budget impact of publicly funding liquid biopsy, as well as the experiences, preferences, and values of people with lung cancer.
Autoría: Ontario Health
Año de publicación: 2020